New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
16:21 EDTABC, AMGNAmgen gets court approval in previously announced $762M settlement with FDA
U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by Amgen (AMGN) for illegally introducing a misbranded drug into interstate commerce, and approved Amgen’s global settlement with the United States in which Amgen agreed to pay $762M to resolve criminal and civil liability arising from its sale and promotion of certain drugs. Under the terms of the criminal plea agreement, Amgen will pay a criminal fine of $136M and criminal forfeiture in the amount of $14M. As part of the civil settlement, Amgen has agreed to pay $612M, of which $587.2M is to the United States and $24.8M to the states, to resolve claims that it caused false claims to be submitted to Medicare, Medicaid and other government insurance programs. In a separate civil settlement, International Nephrology Network, renamed Integrated Nephrology Network, a subsidiary of AmerisourceBergen Corporation (ABC), has also agreed to pay $15M to resolve civil liability arising from its role in the marketing of Aranesp. Reference Link
News For AMGN;ABC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:04 EDTAMGNWest Pharmaceutical's Daikyo Crystal Zenith selected by Amgen
Subscribe for More Information
February 10, 2016
07:15 EDTAMGNLeerink to hold a conference
Subscribe for More Information
February 8, 2016
15:59 EDTAMGNU.K. cost regulator reverses stance on Amgen's Repatha, PharmaTimes says
The U.K.'s National Institute for Health and Care Excellence has reversed its prior decision barring patients from accessing Amgen's cholesterol treatment Repatha, reports PharmaTimes. The agency will now allow use of the drug, alone or in combination with other therapies, for various classes of patients, though only at a 140mg biweekly dose and only as long as the company continues to offer certain discounts, the report noted. Reference Link
February 5, 2016
09:26 EDTAMGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:03 EDTAMGNAmgen resumed with a Market Perform at Leerink
Leerink analyst Geoffrey Porges resumed coverage of Amgen with a Market Perform rating and $179 price target.
February 4, 2016
19:15 EDTAMGNAmgen reinitiated with a Market Perform at Leerink
Target $179.
16:28 EDTAMGNAmgen reports BLINCYTO study met primary endpoint, stopped early for efficacy
Amgen announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The independent data monitoring committee recommended, and Amgen has accepted, that the study end early for efficacy. The BLINCYTO adverse events observed in the TOWER study were consistent with the known safety profile of BLINCYTO. Secondary endpoints are currently being evaluated.
16:02 EDTAMGNAmgen says trial of Repatha meets co-primary endpoints
Subscribe for More Information
11:46 EDTABCOptions with increasing put volume
Subscribe for More Information
07:06 EDTABCAmerisourceBergen, Publix announce distribution agreement
Subscribe for More Information
06:49 EDTABCAmerisourceBergen cuts FY16 adjusted EPS to $5.73-$5.83 from $5.73-$5.90
Subscribe for More Information
06:47 EDTABCAmerisourceBergen announced distribution agreement with Publix
Subscribe for More Information
06:46 EDTABCAmerisourceBergen reports Q1 Pharmaceutical Distribution revenue $35.2B
06:46 EDTABCAmerisourceBergen reports Q1 adjusted EPS $1.27, consensus $1.25
Subscribe for More Information
February 3, 2016
14:48 EDTABCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Philip Morris (PM), consensus 81c... AstraZeneca (AZN), consensus 88c... Occidental Petroleum (OXY), consensus (12c)... ConocoPhillips (COP), consensus (65c)... Cigna (CI), consensus $1.80... Intercontinental Exchange (ICE), consensus $3.01... Boston Scientific (BSX), consensus 25c... Charter Communications (CHTR), consensus (12c)... Ralph Lauren (RL), consensus $2.13... Dunkin' Brands (DNKN), consensus 50c... GrubHub (GRUB), consensus 14c... Level 3 (LVLT), consensus 53c... AmerisourceBergen (ABC), consensus $1.25... Cummins (CMI), consensus $2.11.
08:57 EDTAMGNPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
08:48 EDTAMGNWorkday appoints Diana McKenzie as Chief Information Officer
Subscribe for More Information
February 2, 2016
08:53 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:25 EDTAMGNAlder pullback Friday a buying opportunity, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use